[go: up one dir, main page]

FR2938332B1 - Test predictif de la neutralisation de l'activite asparaginase - Google Patents

Test predictif de la neutralisation de l'activite asparaginase

Info

Publication number
FR2938332B1
FR2938332B1 FR0857604A FR0857604A FR2938332B1 FR 2938332 B1 FR2938332 B1 FR 2938332B1 FR 0857604 A FR0857604 A FR 0857604A FR 0857604 A FR0857604 A FR 0857604A FR 2938332 B1 FR2938332 B1 FR 2938332B1
Authority
FR
France
Prior art keywords
neutralization
asparaginase activity
predictive test
predictive
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0857604A
Other languages
English (en)
Other versions
FR2938332A1 (fr
Inventor
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0857604A priority Critical patent/FR2938332B1/fr
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to KR1020117012739A priority patent/KR101803027B1/ko
Priority to ES09747859.8T priority patent/ES2447165T3/es
Priority to JP2011535120A priority patent/JP5771149B2/ja
Priority to AU2009312702A priority patent/AU2009312702B2/en
Priority to US13/127,756 priority patent/US8852880B2/en
Priority to PCT/EP2009/064793 priority patent/WO2010052315A1/fr
Priority to EP09747859.8A priority patent/EP2358894B1/fr
Priority to CN200980154044.7A priority patent/CN102272323B/zh
Priority to CA2743020A priority patent/CA2743020C/fr
Publication of FR2938332A1 publication Critical patent/FR2938332A1/fr
Priority to IL212643A priority patent/IL212643A/en
Application granted granted Critical
Publication of FR2938332B1 publication Critical patent/FR2938332B1/fr
Priority to US14/489,556 priority patent/US9580739B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G01N2333/982—Asparaginase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0857604A 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase Expired - Fee Related FR2938332B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0857604A FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase
CN200980154044.7A CN102272323B (zh) 2008-11-07 2009-11-06 用于预测对天冬酰胺酶活性的中和作用的测试
JP2011535120A JP5771149B2 (ja) 2008-11-07 2009-11-06 アスパラギナーゼ活性の中和を推定するための検査法
AU2009312702A AU2009312702B2 (en) 2008-11-07 2009-11-06 Test for predicting neutralization of asparaginase activity
US13/127,756 US8852880B2 (en) 2008-11-07 2009-11-06 Test for predicting neutralization of asparaginase activity
PCT/EP2009/064793 WO2010052315A1 (fr) 2008-11-07 2009-11-06 Essai pour la prédiction de la neutralisation de l'activité de l'asparaginase
KR1020117012739A KR101803027B1 (ko) 2008-11-07 2009-11-06 아스파라기나아제 활성의 중화를 예측하기 위한 시험법
ES09747859.8T ES2447165T3 (es) 2008-11-07 2009-11-06 Prueba para predecir la neutralización de actividad de asparaginasa
CA2743020A CA2743020C (fr) 2008-11-07 2009-11-06 Essai pour la prediction de la neutralisation de l'activite de l'asparaginase
EP09747859.8A EP2358894B1 (fr) 2008-11-07 2009-11-06 Essai pour la prédiction de la neutralisation de l'activité de l'asparaginase
IL212643A IL212643A (en) 2008-11-07 2011-05-03 Methods for predicting asparaginase activity in a patient and asparaginase for the treatment of aspartaginase-sensitive pathologies
US14/489,556 US9580739B2 (en) 2008-11-07 2014-09-18 Test for predicting neutralization of asparaginase activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0857604A FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase

Publications (2)

Publication Number Publication Date
FR2938332A1 FR2938332A1 (fr) 2010-05-14
FR2938332B1 true FR2938332B1 (fr) 2011-11-25

Family

ID=40491016

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0857604A Expired - Fee Related FR2938332B1 (fr) 2008-11-07 2008-11-07 Test predictif de la neutralisation de l'activite asparaginase

Country Status (11)

Country Link
US (2) US8852880B2 (fr)
EP (1) EP2358894B1 (fr)
JP (1) JP5771149B2 (fr)
KR (1) KR101803027B1 (fr)
CN (1) CN102272323B (fr)
AU (1) AU2009312702B2 (fr)
CA (1) CA2743020C (fr)
ES (1) ES2447165T3 (fr)
FR (1) FR2938332B1 (fr)
IL (1) IL212643A (fr)
WO (1) WO2010052315A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN104394884A (zh) * 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
DK3107563T3 (da) 2014-02-21 2021-05-25 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Glycomålrettede terapeutiske midler
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
JP2019501655A (ja) 2016-01-11 2019-01-24 ルビウス セラピューティクス， インコーポレイテッド 免疫適応症のためのマルチモーダル治療用細胞系に関連する組成物および方法
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN119023960A (zh) * 2024-07-30 2024-11-26 中国人民解放军海军军医大学 免疫磁分离联合底物肽以lc-ms/ms特异性检测门冬酰胺酶活性的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR408667A (fr) 1909-11-05 1910-04-02 Richard Alexander Katz Hangar de fortune pour ballons dirigeables
FR2873925B1 (fr) * 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
WO2007103290A2 (fr) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Substances et méthodes thérapeutiques axées sur l' asparagine synthétase et l'asparaginase
WO2008063663A2 (fr) * 2006-11-21 2008-05-29 University Of Southern California Dosages à base de poly(éthylèneglycol) pour la détection d'anticorps et trousses destinées à la mise en oeuvre de ces dosages
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas

Also Published As

Publication number Publication date
US20120121570A1 (en) 2012-05-17
AU2009312702A1 (en) 2010-05-14
CN102272323B (zh) 2017-03-22
EP2358894B1 (fr) 2014-01-08
US9580739B2 (en) 2017-02-28
AU2009312702B2 (en) 2012-06-28
IL212643A (en) 2015-04-30
JP5771149B2 (ja) 2015-08-26
US8852880B2 (en) 2014-10-07
US20150071894A1 (en) 2015-03-12
KR101803027B1 (ko) 2017-11-29
CA2743020A1 (fr) 2010-05-14
IL212643A0 (en) 2011-07-31
WO2010052315A1 (fr) 2010-05-14
KR20110097806A (ko) 2011-08-31
JP2012507998A (ja) 2012-04-05
CA2743020C (fr) 2018-12-18
FR2938332A1 (fr) 2010-05-14
CN102272323A (zh) 2011-12-07
EP2358894A1 (fr) 2011-08-24
ES2447165T3 (es) 2014-03-11

Similar Documents

Publication Publication Date Title
FR2938332B1 (fr) Test predictif de la neutralisation de l'activite asparaginase
EP2317847A4 (fr) Inhibition sélective d'expression de protéine de polyglutamine
BRPI0907918A2 (pt) Ácidos sulfoperoxicarxílicos, sua preparação e métodos de utilizção como agentes alvejantes e antimicrobianos
BRPI0814425A2 (pt) Diferenciação de células-tronco embrionárias humanas
BRPI0919448A2 (pt) rastreamento de folículos pilosos
BRPI1007939A2 (pt) "identificação de aspectos de consulta"
EP2368114A4 (fr) Prédiction et prévention de l' éclampsisme
BRPI0814026A2 (pt) Modificação química de ácidos gordos maleatados
EP2446801A4 (fr) Gaine de rinçage d'endoscope
EP2142287A4 (fr) Inhibiteurs de la déméthylase spécifique de la lysine
EP1898903A4 (fr) Inhibiteurs de l'activite akt
EP2299825A4 (fr) Inhibiteurs de l'activité akt
EP2334226A4 (fr) Évaluation cognitive et linguistique utilisant l'oculométrie
EP1982660A4 (fr) Endoscope de traitement
EP2379753A4 (fr) Analyse d'acides nucléiques de cellules uniques
EP2406250A4 (fr) Inhibiteurs de l'activité akt
EP2321654A4 (fr) Classement d états d'activité
EP2306836A4 (fr) Modulateurs de l expression de la protéine bmi-1
EP2313434A4 (fr) Anticorps neutralisant des neurotoxines botuliniques
EP2380567A4 (fr) Inhibiteur de la production de mélanine
EP2307035A4 (fr) Traitement de l'épilepsie
BRPI0921026A2 (pt) avaliação do sistema circulatório de um indivíduo
EP2653858A4 (fr) Procédé d'analyse de détérioration
BRPI0919707A2 (pt) utilização de ácido graxo dessaturases de hemiselmis spp
FR2976082B1 (fr) Methode de determination de l'activite de degradation de la matrice de fibrine d'un agent de detersion

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20230705